Kovitz Investment Group Partners LLC acquired a new position in shares of Celgene Corporation (NASDAQ:CELG) in the first quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 3,095 shares of the biopharmaceutical company’s stock, valued at approximately $385,000.

Several other large investors also recently bought and sold shares of the stock. Diversified Trust Co boosted its position in shares of Celgene Corporation by 0.4% during the 1st quarter. Diversified Trust Co now owns 2,342 shares of the biopharmaceutical company’s stock worth $291,000 after purchasing an additional 9 shares during the period. South Texas Money Management Ltd. boosted its position in shares of Celgene Corporation by 0.6% during the 1st quarter. South Texas Money Management Ltd. now owns 2,453 shares of the biopharmaceutical company’s stock worth $305,000 after purchasing an additional 15 shares during the period. Flagship Harbor Advisors LLC boosted its position in shares of Celgene Corporation by 0.9% during the 1st quarter. Flagship Harbor Advisors LLC now owns 2,054 shares of the biopharmaceutical company’s stock worth $253,000 after purchasing an additional 18 shares during the period. Keel Point LLC boosted its position in shares of Celgene Corporation by 0.9% during the 1st quarter. Keel Point LLC now owns 3,103 shares of the biopharmaceutical company’s stock worth $386,000 after purchasing an additional 28 shares during the period. Finally, Steinberg Global Asset Management boosted its position in shares of Celgene Corporation by 0.6% during the 1st quarter. Steinberg Global Asset Management now owns 6,594 shares of the biopharmaceutical company’s stock worth $820,000 after purchasing an additional 39 shares during the period. 79.43% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: “Kovitz Investment Group Partners LLC Invests $385,000 in Celgene Corporation (CELG)” was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece on another publication, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The legal version of this piece can be read at https://www.thecerbatgem.com/2017/09/12/kovitz-investment-group-partners-llc-invests-385000-in-celgene-corporation-celg.html.

A number of equities analysts recently weighed in on the stock. Oppenheimer Holdings, Inc. reaffirmed an “outperform” rating and set a $175.00 price objective (up previously from $148.00) on shares of Celgene Corporation in a research report on Monday, July 31st. Cantor Fitzgerald set a $160.00 price objective on shares of Celgene Corporation and gave the stock a “buy” rating in a research report on Thursday, July 27th. BMO Capital Markets reissued an “outperform” rating and issued a $160.00 price target (up previously from $152.00) on shares of Celgene Corporation in a research report on Friday, July 28th. Canaccord Genuity set a $156.00 price target on shares of Celgene Corporation and gave the company a “buy” rating in a research report on Tuesday, June 6th. Finally, BidaskClub raised shares of Celgene Corporation from a “sell” rating to a “hold” rating in a research report on Wednesday, June 21st. One research analyst has rated the stock with a sell rating, seven have given a hold rating and twenty-two have given a buy rating to the stock. Celgene Corporation currently has an average rating of “Buy” and an average price target of $147.31.

Shares of Celgene Corporation (CELG) traded up 0.21% on Tuesday, reaching $141.22. 945,165 shares of the company’s stock traded hands. Celgene Corporation has a 52 week low of $96.93 and a 52 week high of $142.64. The stock has a market capitalization of $110.48 billion, a PE ratio of 43.73 and a beta of 1.89. The company has a 50 day moving average of $134.21 and a 200-day moving average of $126.84.

Celgene Corporation (NASDAQ:CELG) last issued its earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.82 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.61 by $0.21. The company had revenue of $3.27 billion for the quarter, compared to analysts’ expectations of $3.23 billion. Celgene Corporation had a net margin of 21.35% and a return on equity of 68.51%. The firm’s revenue was up 18.7% compared to the same quarter last year. During the same period in the prior year, the company earned $1.44 earnings per share. Equities research analysts forecast that Celgene Corporation will post $7.32 earnings per share for the current year.

In other Celgene Corporation news, insider Robert J. Hugin sold 175,970 shares of the stock in a transaction on Thursday, June 22nd. The shares were sold at an average price of $134.14, for a total transaction of $23,604,615.80. Following the sale, the insider now directly owns 1,033,909 shares of the company’s stock, valued at $138,688,553.26. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Rupert Vessey sold 4,785 shares of the stock in a transaction on Thursday, June 15th. The stock was sold at an average price of $120.18, for a total transaction of $575,061.30. Following the sale, the insider now directly owns 4,004 shares in the company, valued at $481,200.72. The disclosure for this sale can be found here. Insiders have sold 263,011 shares of company stock worth $35,078,473 over the last three months. 0.95% of the stock is owned by corporate insiders.

About Celgene Corporation

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Institutional Ownership by Quarter for Celgene Corporation (NASDAQ:CELG)

Receive News & Stock Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related stocks with our FREE daily email newsletter.